NCT02552212 · BASELINE
Baseline characteristics
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- denoms
- counts
- group Id
- BG000
- value
- 158
- group Id
- BG001
- value
- 159
- group Id
- BG002
- value
- 317
- units
- Participants
- groups
- description
- Matching placebo to certolizumab pegol (CZP) injections were administered every 2 weeks from Week 0 onwards.
- id
- BG000
- title
- Placebo
- description
- Certolizumab pegol (CZP) 400 mg subcutaneous (sc) on Weeks 0, 2 and 4, followed by 200 mg CZP sc every 2 weeks (Q2W) from Week 6 onwards.
- id
- BG001
- title
- CZP 200 mg Q2W
- id
- BG002
- title
- Total Title
- measures
- classes
- categories
- measurements
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 4
- title
- <=18 years
- measurements
- group Id
- BG000
- value
- 154
- group Id
- BG001
- value
- 156
- group Id
- BG002
- value
- 310
- title
- Between 18 and 65 years
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 3
- title
- >=65 years
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Age, Categorical
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- spread
- 10.8
- value
- 37.4
- group Id
- BG001
- spread
- 10.5
- value
- 37.3
- group Id
- BG002
- spread
- 10.6
- value
- 37.3
- dispersion Type
- STANDARD_DEVIATION
- param Type
- MEAN
- title
- Age, Continuous
- unit Of Measure
- years
- classes
- categories
- measurements
- group Id
- BG000
- value
- 82
- group Id
- BG001
- value
- 81
- group Id
- BG002
- value
- 163
- title
- Female
- measurements
- group Id
- BG000
- value
- 76
- group Id
- BG001
- value
- 78
- group Id
- BG002
- value
- 154
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 8
- group Id
- BG001
- value
- 5
- group Id
- BG002
- value
- 13
- title
- Asian
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 1
- title
- Black
- measurements
- group Id
- BG000
- value
- 148
- group Id
- BG001
- value
- 152
- group Id
- BG002
- value
- 300
- title
- White
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 3
- title
- Other/mixed
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Race/Ethnicity, Customized
- unit Of Measure
- Participants
- population Description
- Baseline Characteristics refer to the Randomized Set witch consisted of all subjects randomized into the study.
Complete source fields
- denoms
- counts
- group Id
- BG000
- value
- 158
- group Id
- BG001
- value
- 159
- group Id
- BG002
- value
- 317
- units
- Participants
- groups
- description
- Matching placebo to certolizumab pegol (CZP) injections were administered every 2 weeks from Week 0 onwards.
- id
- BG000
- title
- Placebo
- description
- Certolizumab pegol (CZP) 400 mg subcutaneous (sc) on Weeks 0, 2 and 4, followed by 200 mg CZP sc every 2 weeks (Q2W) from Week 6 onwards.
- id
- BG001
- title
- CZP 200 mg Q2W
- id
- BG002
- title
- Total Title
- measures
- classes
- categories
- measurements
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 4
- title
- <=18 years
- measurements
- group Id
- BG000
- value
- 154
- group Id
- BG001
- value
- 156
- group Id
- BG002
- value
- 310
- title
- Between 18 and 65 years
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 3
- title
- >=65 years
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Age, Categorical
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- spread
- 10.8
- value
- 37.4
- group Id
- BG001
- spread
- 10.5
- value
- 37.3
- group Id
- BG002
- spread
- 10.6
- value
- 37.3
- dispersion Type
- STANDARD_DEVIATION
- param Type
- MEAN
- title
- Age, Continuous
- unit Of Measure
- years
- classes
- categories
- measurements
- group Id
- BG000
- value
- 82
- group Id
- BG001
- value
- 81
- group Id
- BG002
- value
- 163
- title
- Female
- measurements
- group Id
- BG000
- value
- 76
- group Id
- BG001
- value
- 78
- group Id
- BG002
- value
- 154
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 8
- group Id
- BG001
- value
- 5
- group Id
- BG002
- value
- 13
- title
- Asian
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 1
- title
- Black
- measurements
- group Id
- BG000
- value
- 148
- group Id
- BG001
- value
- 152
- group Id
- BG002
- value
- 300
- title
- White
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 3
- title
- Other/mixed
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Race/Ethnicity, Customized
- unit Of Measure
- Participants
- population Description
- Baseline Characteristics refer to the Randomized Set witch consisted of all subjects randomized into the study.
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice
Triangle